检索结果-南通市图书馆

Development and validation of the NCC‐BC‐A scale to assess patient‐reported outcomes for breast cancer patients in China

引用

Cancer Innovation 2024年第6期3卷 45-57页

作者： Fei Ma Xiaoyan Yan xiuwen guan Tianmou Liu 无 National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina Clinical Research Institute Institute of Advanced Clinical MedicinePeking UniversityBeijingChina Department of Epidemiology and Biostatistics School of Public HealthPeking UniversityBeijingChina PRO‐BC China Standards Committee

Background:The commonly used international patient‐reported outcome scales for breast cancer were developed before the advent of multiple targeted therapies and immunotherapies,rendering them potentially insufficient for current clinical ***,it is necessary to develop a specific patient‐reported outcome scale tailored for breast cancer patients in China to optimize the management model for these ***:A comprehensive literature search was performed in the PubMed,Embase,Wanfang,and CNKI databases to extract dimensions and items for a potential patient‐reported outcome *** Delphi method was used to modify,add,subtract,and adjust the language of items until the experts reached a consensus on the first *** draft was further refined using a cognitive test and a *** optimized scale was used for a formal survey,and the items were further analyzed and screened using metrics such as the coefficient of variation,correlation coefficient,internal item consistency,factor analysis,reliability,and ***:A total of 10,954 articles were analyzed,and 237 were used to create a pool of 277 patient‐reported outcome *** two rounds of Delphi expert consultation,the experts'authority coefficients were 0.739 and *** a cognitive test,several items were adjusted to enhance *** adjustments were made following a presurvey of 200 advanced breast cancer patients,resulting in a 38‐item patient‐reported outcomes scale,termed NCC‐BC‐*** the national formal survey,588 advanced breast cancer patients *** component analysis showed good consistency among the items and sufficient difference between the *** results were normally distributed with good *** Cronbach'sαcoefficient of the scale was 0.925 and the test–retest reliability was ***:The NCC‐BC‐A scale has high validity and *** comprehensively considered the characteristics of systemic trea

关键词： breast cancer patient‐reported outcome quality of life

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

A nanosystem of copper(II)-disulfiram for cancer treatment with high efficacy and few side effects

引用

Frontiers of Materials Science 2021年第4期15卷 553-566页

作者： Liping ZHAO Xiaoxia WANG Mingxia JIANG Xinghan WU Mogen ZHANG xiuwen guan Jinlong MA Weifen ZHANG College of Pharmacy Weifang Medical UniversityWeifang 261053China Department of Pathology Weifang Medical UniversityWeifang 261053China School of Clinical Medicine Weifang Medical UniversityWeifang 261053China Collaborative Innovation Center for Target Drug Delivery System Weifang Medical UniversityWeifang 261053China Shandong Engineering Research Center for Smart Materials and Regenerative Medicine Weifang Medical UniversityWeifang 261053China

Developing chemotherapy drugs with high efficacy and few side effects has been a bottleneck problem that requires an efficient *** active cancer treatment ingredient disulfiram(DSF),inspired by the copper(II)diethyldithiocarbamate complex(CuET),can be used in a one-pot synthesis method to construct a CuET delivery nanosystem(CuET-ZIFCu@HA).Due to the high biocompatibility,targeting of CD44 overexpressed cancer cells,and acid response of zeolitic imidazolate framework(ZIF)materials of hyaluronic acid(HA),we realized that CuET-ZIFCu@HA could become an effective and highly selective cancer *** in vivo and in vitro experiments have demonstrated that CuET-ZIFCu@HA has robust anti-tumor properties without evident side *** research provided a promising strategy for DSF nanosystems that involves simple preparation and high efficacy,both of which are key to reusing DSF in cancer treatment.

关键词： disulfiram copper(II)diethyldithiocarbamate complex zeolitic imidazolate framework targeted therapy

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Synergetic burns treatment by self-adaption release system combined with cold atmospheric plasma

引用

Science China(Technological Sciences) 2023年第10期66卷 2808-2823页

作者： WANG XiaoXia LIU ZhiJun ZHAO LiPing YANG HuiJie QIN JiaMin ZHANG JingQi ZHAO JiaXuan guan xiuwen ZHANG WeiFen MA JinLong School of Pharmacy Weifang Medical UniversityWeifang 261053China Department of Microbiology School of Basic Medical SciencesWeifang Medical UniversityWeifang 261053China Shandong Engineering Research Center for Smart Materials and Regenerative Medicine Weifang Medical UniversityWeifang 261053China Collaborative Innovation Center for Target Drug Delivery System Weifang Medical UniversityWeifang 261053China

In the tissue remodeling stage of burns,excessive medical therapy can cause scarring by promoting excessive fibroblast proliferation and collagen *** atmospheric plasma(CAP)has emerged in biomedicine for its excellent sterilization and wound-healing function,which is expected to reduce the use of drugs in burns ***,a novel therapy that could rapidly heal burns was developed using a combined self-adaption release system with *** self-adaption release system(Cur-ZIF8@HA)used curcumin(Cur)as the therapeutic drug and ZIF-8 modified with hyaluronic acid(HA)as the *** vitro study results showed that combined treatment methods can inactivate bacteria and enhance fibroblast cells'migration and *** vivo animal wound healing studies have demonstrated that the synergistic treatment of Cur-ZIF8@HA and CAP can help fibroblast proliferation and stimulate angiogenesis,indicating effective wound *** importantly,CAP can reduce collagen synthesis in granulation tissue recombination and further inhibit scar formation by combining with CurZIF8@*** the biomedical field,these findings underscore to a large extent that our research will open up new possibilities for the interaction of nanotechnology with new technologies of physical principles.

关键词： cold atmospheric plasma pH-sensitive release burns treatment nanoparticle

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

The molecular tumor burden index as a response evaluation criterion in breast cancer

引用

Signal Transduction and Targeted Therapy 2021年第8期6卷 2494-2501页

作者： Zongbi Yi Fei Ma Guohua Rong Binliang Liu Yanfang guan Jin Li Xiaoying Sun Wenna Wang xiuwen guan Hongnan Mo Jiani Wang Haili Qian Binghe Xu Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina Geneplus-Beijing Institute BeijingChina Department of Medical Oncology Huanxing Cancer HospitalBeijingChina State Key Laboratory of Molecular Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina

Circulating tumor DNA(ctDNA)is a potential biomarker of prognosis and therapeutic *** conducted this study to explore the role of the molecular tumor burden index(mTBI)in ctDNA as a therapeutic response and prognostic biomarker in a larger cohort prospective phase III randomized multicenter *** collected 291 plasma samples from 125 metastatic breast cancer patients from the CAMELLIA study(NCT01917279).Target-capture deep sequencing of 1021 genes was performed to detect somatic variants in ctDNA from the plasma *** pretreatment mTBI value was correlated with tumor burden(P=0.025).Patients with high-level pretreatment mTBI had shorter overall survival than patients with low-level pretreatment mTBI,and the median overall survival was 40.9 months and 68.4 months,respectively(P=0.011).Patients with mTBI decrease to less than 0.02%at the first tumor evaluation had longer progression-free survival and overall survival(P<0.001 and P=0.007,respectively).The mTBI has good sensitivity to identify complete response/partial response and progressive disease based on computed tomography scans(88.5%and 87.5%,respectively).The patients classified as molecular responders had longer progression-free survival and overall survival than the nonmolecular responders in the overall cohort(P<0.001 and P=0.036,respectively),as well as in the cohort in which computed tomography scans were defined as representing stable disease(P=0.027 and P=0.015,respectively).The mTBI in ctDNA detected in liquid biopsies is a potential biomarker of therapeutic response and prognosis in patients with metastatic breast cancer.

关键词： breast cancer index

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Pyrotinib plus capecitabine could significantly improve overall survival in HER2-positive metastatic breast cancer

引用

Signal Transduction and Targeted Therapy 2023年第4期8卷 1378-1380页

作者： xiuwen guan Fei Ma Qiao Li Shanshan Chen Ying Fan Jiayu Wang Yang Luo Pin Zhang Qing Liand Binghe Xu Department of Medical Oncology and State Key Laboratory of Molecular Oncology National Cancer Center/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina

Dear Editor,The irreversible pan-ErbB tyrosine kinase inhibitors(TKIs),including neratinib and pyrotinib,demonstrated more complete inhibition towards ErbB-family and promising antitumor activity compared to lapatinib,a reversible TKI.1 In the phase III NALA study for HER2-positive metastatic breast cancer(MBC)who were progressed after two lines of HER2-targeted regimens,2 significant improvement was observed in progression-free survival(PFS)in patients receiving neratinib combined with capecitabine when compared to lapatinib plus capecitabine(L+C)***,the 2.2-month PFS improvement in neratinib plus capecitabine cohort failed to translate to a significant benefit in the overall survival(OS,24.0 vs 22.2 months,P=0.2086).2 While another irreversible TKI,pyrotinib combined with capecitabine(P+C)achieved clinically and statistically significant improvement in the PFS and a trend of benefits in the OS when compared to the L+C group,based on the interim analysis(with the cutoff of March 31,2019)of the phase III PHOEBE study.3 Generally speaking,current evidence was still limited regarding the survival data of irreversible TKIs.

关键词： capecitabine HER2 breast

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Pooled analyses of randomized controlled trials onpyrotinib plus capecitabine and a rethink of the first-line options for HER2-positive relapsed or metastatic breast cancer

引用

Cancer Innovation 2022年第2期1卷 119-123页

作者： xiuwen guan Fei Ma Binghe Xu Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina Department of Medical Oncology and Clinical Trial Center National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina

Human epidermal growth factor receptor 2(HER2)-positive breast cancer,which accounts for 15%-20% of breast cancers,is associated with aggressive tumor behavior and conferred a poor outcome before the era of HER2-targeted *** advent of anti-HER2 antibodies(trastuzumab and pertuzumab),antibody-drug conjugates(ADCs,ado-trastuzumab emtansine and trastuzumab deruxtecan),and HER2‐tyrosine kinase inhibitors(TKIs,neratinib and lapatinib),have dramatically improved the treatment response and survival of this aggressive subtype.

关键词： breast cancer tyrosine kinase inhibitor HER2-targeted therapy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

The association between early-onset cardiac events caused by neoadjuvant or adjuvant chemotherapy in triple-negative breast cancer patients and some novel autophagy-related polymorphisms in their genomic DNA: a real-world study

引用

Cancer Communications 2018年第1期38卷 759-769页

作者： Binliang Liu Tao An Meiying Li Zongbi Yi Chunxiao Li Xiaoying Sun xiuwen guan Lixi Li Yanfeng Wang Yuhui Zhang Binghe Xu Fei Ma Yixin Zeng Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021P.R.China State Key Laboratory of Cardiovascular Disease Heart Failure CenterFuwai HospitalNational Center for Cardiovascular DiseaseChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100037P.R.China Shandong Cancer Hospital and Institute Shandong UniversityJinan 250117ShandongP.R.China State Key Laboratory of Molecular Oncology Cancer Institute/HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021P.R.China Department of Medical Oncology Cancer Hospital of HuanxingBeijing 100065P.R.China Department of Comprehensive Oncology National Cancer Center/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021P.R.China Chinese Academy of Medical Sciences and Peking Union Medical College Beijing 100730P.R.China Collaborative Innovation Center for Cancer Medicine State Key Laboratory of Oncology in South ChinaSun Yat-sen University Cancer Center651 Dongfeng Road EastGuangzhou 510060GuangdongP.R.China

Background:An increasing number of cancer patients die of cardiovascular *** cardiotoxicity of chemo-therapy is particularly important in triple-negative breast cancer(TNBC)with limited therapeutic *** autophagy is an important mechanism of *** research was aimed to investigate the cardiotoxicity of chemotherapy in TNBC,screen the susceptible population,and determine the relationship between cardiotoxicity and autophagy-related ***:From a total of 2450 stage I-III TNBC patients,147 met the inclusion criteria and finally ***-cardiography(ECG)was performed before most chemotherapy cycles,and echocardiography(UCG)was performed according to clinical *** ECG and UCG records were re-interpreted by cardiologists at the National Center for Cardiovascular Disease,Fuwai *** to the National Center for Biotechnology Information and the Catalog of Somatic Mutations in Cancer database,we selected 25 single nucleotide polymorphisms(SNPs)related to autophagy and genotyped the 147 TNBC ***-sample T tests,Chi squared tests,and logistic regression models were employed for the ***:Only 46(31.3%)patients had normal ECG records after every chemotherapy *** the 16 patients who underwent UCG,2(12.5%)had a reversible decrease of left ventricular ejection *** use of anthracyclines and excessive alcohol consumption were risk factors of ECG *** the continuation of chemotherapy,heart rate gradually *** were associated with QRS duration abnormalities(P=0.043).After genotyping for 25 autophagy-related SNPs,we found that the G allele of autophagy-related 13(ATG13)rs10838611 was significantly associated with ECG abnormalities(odds ratio=2.258,95%confidence interval=1.318-3.869;P=0.003).Conclusion:ECG abnormalities caused by chemotherapy are common in the real ***-related SNPs are associated with chemotherapy-induced cardi

关键词： Triple-negative breast cancer Chemotherapy Cardiotoxicity Autophagy Single nucleotide polymorphisms

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer

引用

Cancer Communications 2019年第1期39卷 514-525页

作者： Shaoyan Lin Jian Yue xiuwen guan Peng Yuan Jiayu Wang Yang Luo Ying Fan Ruigang Cai Qiao Li Shanshan Chen Pin Zhang Qing Li Fei Ma Binghe Xu Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences&Peking Union Medical CollegeNo.17Panjiayuan NanliChaoyang DistrictBeijing 100021P.R.China Department of VIP Medical Services National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences&Peking Union Medical CollegeBeijing 100021P.R.China

Background:Breast cancer is a global problem,and a large number of new cases are diagnosed every ***-abine is effective in patients with metastatic breast cancer(MBC).Hand-foot syndrome(HFS)is a common adverse effect of *** this study,we investigated the association between single nucleotide polymorphisms(SNPs)in genes involved in capecitabine metabolism pathways and capecitabine-induced HFS in Chinese patients with MBC to identify some predictive genetic ***:We selected 3 genes involved in capecitabine metabolism and screened genetic variants in these target *** genotyped a total of 22 SNPs in the thymidylate synthase gene(TYMS),the methylene tetrahydrofolate reductase gene(MTHFR),and the ribonucleotide reductase M1 gene(RRM1)in 342 MBC patients treated with capecit-abine-based *** genotype distributions of each SNP in patients with and without HFS were assessed using Pearson’sχ^(2)test,and the relationship between HFS and genotypes of SNPs was determined using logistic regression *** association between SNPs and their corresponding gene expression was analyzed using the Blood expression quantitative trait loci(eQTL)browser online ***:We found 4 positive sites for HFS in the TYMS and MTHFR genes:TYMS rs2606241(P=0.022),TYMS rs2853741(P=0.019),MTHFR rs3737964(P=0.029),and MTHFR rs4846048(P=0.030).Logistic regression analyses showed that the genotype AG of MTHFR rs3737964[odds ratio(OR)=0.54,95%confidence interval(CI)0.31-0.97,P=0.038]and MTHFR rs4846048(OR=0.54,95%CI 0.30-0.98,P=0.042)were protective factors of HFS,whereas the genotype CT of TYMS rs2853741(OR=2.25,95%CI 1.31-3.87,P=0.012)increased the risk of *** association between the genotype GT of TYMS rs2606241(OR=1.27,95%CI 0.73-2.23,P=0.012)and HFS was *** eQTL analyses confirmed that the alleles of rs3737964 and rs4846048 affected the gene expression levels of MTHFR in ***:We have identified four potentiall

关键词： Capecitabine Polymorphism Metastatic breast cancer Hand-foot syndrome TYMS MTHFR

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Antibody-drug conjugates in HER2-positive breast cancer

引用

Chinese Medical Journal 2022年第3期135卷 261-267页

作者： Lixi Li Di Zhang Binliang Liu Dan Lv Jingtong Zhai xiuwen guan Zongbi Yi Fei Ma Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China

Antibody-drug conjugates(ADCs)combine the high specificity of monoclonal antibodies with the high anti-tumor activity of small molecular cytotoxic *** anti-tumor activity of ADCs is mainly achieved by the direct blocking of the receptor by monoclonal antibodies,direct action and bystander effect of cytotoxic drugs,and antibody-dependent cell-mediated cytotoxicity and complement-dependent *** have been used in adjuvant therapy and rescue treatment of human epidermal receptor 2(HER2)-positive breast cancer,greatly improving the prognosis of breast cancer *** ongoing clinical trials of ADC for breast cancer and other solid tumors proved the potential of ADCs will provide more promising treatment options for patients with malignant *** review introduces the mechanism and latest clinical progress of ADC drugs approved for HER2-positive breast cancer to guide clinical practice and conduct research.

关键词： Antibody-drug conjugate HER2-positive Breast cancer T-DM1 DS-8201

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer

引用

Cancer Communications 2019年第1期39卷 1-10页

作者： xiuwen guan Fei Ma Chunxiao Li Shiyang Wu Shangying Hu Jiefen Huang Xiaoying Sun Jiayu Wang Yang Luo Ruigang Cai Ying Fan Qiao Li Shanshan Chen Pin Zhang Qing Li Binghe Xu Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeNo.17Panjiayuan NanliChaoyang DistrictBeijing 100021P.R.China State Key Laboratory of Molecular Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021P.R.China SurExam Bio-Tech Guangzhou Technology Innovation BaseScience CityGuangzhou 510000GuangdongP.R.China Department of Cancer Epidemiology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021P.R.China Department of Medical Oncology Huanxing Cancer HospitalBeijing 100021P.R.China

Background:Epithelial-mesenchymal transition(EMT)is implicated in the metastatic process and presents a chal-lenge to epithelial cell adhesion molecule-based detection of circulating tumor cells(CTCs),which have been demon-strated to be a prognostic indicator in metastatic breast *** evidence has indicated that heterogeneity of CTCs based on EMT markers is associated with disease progression,no standard recommendations have been established for clinical *** study aimed to evaluate the prognostic significance of dynamic CTC detection based on EMT for metastatic breast cancer ***:We enrolled 108 human epidermal growth factor receptor 2-negative metastatic breast cancer patients from the prospective phase III CAMELLIA study and applied the CanPatrol CTC enrichment technique to identify CTC phenotypes(including epithelial CTCs,biphenotypic epithelial/mesenchymal CTCs,and mesenchymal CTCs)in peripheral blood *** operating characteristic curve analyses of total CTC count and the proportion of mesenchymal CTCs for predicting the 1-year progression-free survival(PFS)rate were conducted to determine the optimal cut-off values,and Kaplan-Meier analysis and Cox proportional hazards regression analysis were performed to investigate the prognostic value of the cut-off values of both total CTC count and the proportion of mesenchymal CTCs in ***:For predicting the 1-year PFS rate,the optimal cut-off value of total CTC count was 9.5(Area under the curve[AUC]=0.538,95%confidence interval[CI]=0.418-0.657),and that of the proportion of mesenchymal CTCs was 10.7%(AUC=0.581,95%CI=0.463-0.699).We used the two cut-off values in combination to forecast PFS in which the total CTC count was equaled to or exceeded 10/5 mL with the proportion of mesenchymal CTCs surpassed 10.7%.Patients who met the combined criteria had significantly shorter median PFS than did those who did not meet the criteria(6.2 vs.9.9 months,P=0.010).A nomog

关键词： Breast cancer Circulating tumor cells Epithelial-mesenchymal transition Prognosis Therapeutic implication

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：